唑来膦酸联合不同剂量姑息放疗治疗乳腺癌骨转移

Oledronic acid concurrent with either high-or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases

目的探讨放疗联合唑来膦酸治疗乳腺癌骨转移的安全性及有效性。方法乳腺癌骨转移患者随机分为高剂量和低剂量放疗组,从放疗开始,所有患者均接受唑来膦酸(4 mg),28 d一周期共6周期。VAS评分和全身骨扫描用来评价治疗效果。结果两组放疗后疼痛评分、累积不良骨事件发生率,及骨扫描结果无明显差别。结论联合唑来膦酸,高剂量放疗和低剂量放疗治疗乳腺癌骨转移,二者疗效相当,但低剂量组治疗时间短,并发症较少。

[ Objective ] In this prospective study, the efficacy and safety of radiotherapy combined with zoledron- ic acid was evaluated. [Methods] Breast cancer patients with painful bone metastases were randomized to either high-or reduced-dose radiotherapy. All patients received zoledronic acid （4 nag） every 28 days from the beginning of radiotherapy. Analgesic and pain scores in addition to visual analog score（~AS） for treatment satisfaction and whole- body bone scintigraphy were evaluated. [ Results ] No significant differences could be found in analgesic or pain scores and bone scintigraphy results between the groups. [ Conclusion ] Reduced-dose radiotherapy produces similar response rates and response durations when used concomitantly with zoledronic acid, but outputs complications.